Literature DB >> 12408184

Elevated plasma phenylalanine concentrations may adversely affect bone status of phenylketonuric mice.

S Yannicelli1, D M Medeiros.   

Abstract

Children with phenylketonuric (PKU) are at risk for fractures. This study used a PKU murine model (PAH(enu-2)) to evaluate effects of moderate dietary protein restriction and elevated plasma phenylalanine concentration impact upon bone status. Fifty-four male weanling PKU and control mice were assigned to either an elemental phenylalanine (Phe)-restricted diet (treated) or Phe-unrestricted diet (untreated) with low or normal protein levels for 56 days. Untreated mice and control mice received equal amounts of dietary Phe; treated mice consumed prescribed dietary Phe to maintain plasma Phe concentrations between 120 and 480micromol/L. Plasma Phe, osteocalcin, and urine deoxypyridinoline (DPD)/creatinine were analysed at baseline and at days 28 and 56. Femur strength, bone mineral density (BMD) and bone mineral content (BMC) were analysed at day 56. Moderate protein restriction did not significantly affect bone status. Mean plasma Phe concentrations were significantly greater in untreated vs treated and control mice (p < 0.0001). Total body weight was significantly less in untreated vs control mice (p < 0.01). Mean femur weight was reduced in untreated mice vs both treated and control mice (p < 0.03). Untreated mice had smaller mean femur length than control mice (p < 0.002). Femur strength was greater in treated mice compared to control mice (p < 0.01) but not compared to untreated mice. No significant difference among groups was found in BMD and BMC. At day 56 there was a statistical trend (p < 0.056) towards higher urine DPD/creatinine excretion in untreated mice than in treated mice. Plasma Phe concentration was positively correlated with urine DPD/creatinine. These data suggested that hyperphenylalaninaemia may adversely affect bone status in PKU mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12408184     DOI: 10.1023/a:1020191515173

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  45 in total

1.  Energy content of diets of variable amino acid composition.

Authors:  M E May; J O Hill
Journal:  Am J Clin Nutr       Date:  1990-11       Impact factor: 7.045

2.  Effect of protein restriction on the messenger RNA contents of bone-matrix proteins, insulin-like growth factors and insulin-like growth factor binding proteins in femur of ovariectomized rats.

Authors:  Y Higashi; A Takenaka; S I Takahashi; T Noguchi
Journal:  Br J Nutr       Date:  1996-06       Impact factor: 3.718

3.  Decreased bone mineralization in children with phenylketonuria under treatment.

Authors:  L Hillman; C Schlotzhauer; D Lee; J Grasela; S Witter; S Allen; R Hillman
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

4.  Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis.

Authors:  P D Delmas; A Schlemmer; E Gineyts; B Riis; C Christiansen
Journal:  J Bone Miner Res       Date:  1991-06       Impact factor: 6.741

5.  Bone mineral status in children with phenylketonuria under treatment.

Authors:  A Al-Qadreh; K H Schulpis; H Athanasopoulou; C Mengreli; A Skarpalezou; I Voskaki
Journal:  Acta Paediatr       Date:  1998-11       Impact factor: 2.299

6.  Experience with adolescents with phenylketonuria returned to phenylalanine-restricted diets.

Authors:  S E Hogan; R D Gates; G W MacDonald; J T Clarke
Journal:  J Am Diet Assoc       Date:  1986-09

7.  Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography.

Authors:  D R Eyre; T J Koob; K P Van Ness
Journal:  Anal Biochem       Date:  1984-03       Impact factor: 3.365

8.  Urinary excretion of hydroxy-pyridinium cross-links of collagen reflects skeletal growth velocity in normal children.

Authors:  F Rauch; E Schönau; H Woitge; T Remer; M Seibel
Journal:  Exp Clin Endocrinol       Date:  1994

9.  Plasma phenylalanine and tyrosine responses to different nutritional conditions (fasting/postprandial) in patients with phenylketonuria: effect of sample timing.

Authors:  F J van Spronsen; M van Rijn; T van Dijk; G P Smit; D J Reijngoud; R Berger; H S Heymans
Journal:  Pediatrics       Date:  1993-10       Impact factor: 7.124

10.  Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption.

Authors:  S P Robins; H Woitge; R Hesley; J Ju; S Seyedin; M J Seibel
Journal:  J Bone Miner Res       Date:  1994-10       Impact factor: 6.741

View more
  6 in total

1.  Nutritional Management of Phenylketonuria.

Authors:  Erin L Macleod; Denise M Ney
Journal:  Ann Nestle Eng       Date:  2010-06

2.  Bone metabolism and the muscle-bone relationship in children, adolescents and young adults with phenylketonuria.

Authors:  Piotr Adamczyk; Aurelia Morawiec-Knysak; Paweł Płudowski; Beata Banaszak; Jacek Karpe; Wojciech Pluskiewicz
Journal:  J Bone Miner Metab       Date:  2010-08-13       Impact factor: 2.626

3.  Cross-sectional study of bone metabolism with nutrition in adult classical phenylketonuric patients diagnosed by neonatal screening.

Authors:  Hironori Nagasaka; Hirokazu Tsukahara; Tomozumi Takatani; Yoshitami Sanayama; Masaki Takayanagi; Toshihiro Ohura; Osamu Sakamoto; Tetsuya Ito; Mika Wada; Makoto Yoshino; Akira Ohtake; Tohru Yorifuji; Satoshi Hirayama; Takashi Miida; Hiroki Fujimoto; Hiroshi Mochizuki; Toshikazu Hattori; Yoshiyuki Okano
Journal:  J Bone Miner Metab       Date:  2011-05-19       Impact factor: 2.626

4.  Bone impairment in phenylketonuria is characterized by circulating osteoclast precursors and activated T cell increase.

Authors:  Ilaria Roato; Francesco Porta; Alessandro Mussa; Lucia D'Amico; Ludovica Fiore; Davide Garelli; Marco Spada; Riccardo Ferracini
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

5.  Increased spontaneous osteoclastogenesis from peripheral blood mononuclear cells in phenylketonuria.

Authors:  F Porta; I Roato; A Mussa; M Repici; E Gorassini; M Spada; R Ferracini
Journal:  J Inherit Metab Dis       Date:  2008-10-17       Impact factor: 4.982

6.  Low bone strength is a manifestation of phenylketonuria in mice and is attenuated by a glycomacropeptide diet.

Authors:  Patrick Solverson; Sangita G Murali; Suzanne J Litscher; Robert D Blank; Denise M Ney
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.